- Home
- BDN vs DNTH Comparison
BDN vs DNTH Comparison
Compare BDN & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDN
- DNTH
- Stock Information
- Founded
- BDN 1986
- DNTH 2015
- Country
- BDN United States
- DNTH United States
- Employees
- BDN N/A
- DNTH N/A
- Industry
- BDN Real Estate Investment Trusts
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- BDN Real Estate
- DNTH Health Care
- Exchange
- BDN Nasdaq
- DNTH Nasdaq
- Market Cap
- BDN 731.6M
- DNTH 606.2M
- IPO Year
- BDN N/A
- DNTH N/A
- Fundamental
- Price
- BDN $3.88
- DNTH $21.49
- Analyst Decision
- BDN Hold
- DNTH Strong Buy
- Analyst Count
- BDN 1
- DNTH 8
- Target Price
- BDN $5.00
- DNTH $53.00
- AVG Volume (30 Days)
- BDN 2.8M
- DNTH 371.6K
- Earning Date
- BDN 07-23-2025
- DNTH 08-11-2025
- Dividend Yield
- BDN 15.56%
- DNTH N/A
- EPS Growth
- BDN N/A
- DNTH N/A
- EPS
- BDN N/A
- DNTH N/A
- Revenue
- BDN $306,596,000.00
- DNTH $6,524,000.00
- Revenue This Year
- BDN $54.81
- DNTH N/A
- Revenue Next Year
- BDN $2.93
- DNTH N/A
- P/E Ratio
- BDN N/A
- DNTH N/A
- Revenue Growth
- BDN N/A
- DNTH 102.36
- 52 Week Low
- BDN $3.41
- DNTH $13.37
- 52 Week High
- BDN $6.54
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- BDN 35.72
- DNTH 58.34
- Support Level
- BDN $3.79
- DNTH $20.00
- Resistance Level
- BDN $4.05
- DNTH $23.21
- Average True Range (ATR)
- BDN 0.12
- DNTH 1.28
- MACD
- BDN -0.03
- DNTH -0.05
- Stochastic Oscillator
- BDN 15.79
- DNTH 58.09
About BDN Brandywine Realty Trust
Brandywine Realty Trust engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties. The company owned and managed properties within five segments. The Philadelphia CBD segment includes properties located in the City of Philadelphia in Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs. The Austin, Texas segment includes properties in the City of Austin, Texas. The Metropolitan Washington, D.C. segment includes properties in Northern Virginia, Washington, D.C. and Southern Maryland. The Other segment includes properties in Camden County, New Jersey and New Castle County, Delaware.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.